| ¿µ¹® | blood clotting, blood coagulation | ÇÑ±Û | Ç÷¾×ÀÀ°í |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀÌ»ó ³ªÁö ¾Ê°Ô ÇÏ´Â °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. ù¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô ÇÏ¸é ¿ì¼± Ç÷°üÀÇ ¼Õ»óºÎÀ§·Î ºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »óó¸¦ ¸·°í ÀÖ´Â Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼ ´õ¿í ´Ü´ÜÇÏ°Ô ÇÏ¿© »óó°¡ ³ Ç÷°ü¿¡¼ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇÏ´Â °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©ÇÏ´Â ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇÏ´Â °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾÙ. Ç÷¾×ÀÀ°í¶õ µÎ¹øÂ° ´Ü°è¸¦ ÁöĪÇÏ´Â ¸»·Î½á ¸Å¿ì º¹ÀâÇÑ ´Ü°è¸¦ °ÅÄ¡´Â ¹ÝÀÀÀ¸·Î ¸¶Áö¸· ´Ü°è´Â ¼¶À¯¼Ò¶ó´Â ¹°ÁúÀÌ ¸¸µé¾îÁ®¼ ÀÌ ¹°ÁúÀÌ Ç÷¼ÒÆÇ°ú ±× ¿ÜÀÇ ¼¼Æ÷¸¦ ´Ü´ÜÇÏ°Ô °íÁ¤½ÃÄÑ Çǰ¡ »óó³ Ç÷°üÀ¸·Î »õ´Â °ÍÀ» ¸·´Â´Ù. À̰ÍÀ» °¡Àå °£´ÜÈ÷ ¼³¸íÇÏÀÚ¸é Å©°Ô ´ÙÀ½°ú °°Àº 3°¡Áö ´Ü°è·Î ÀÌ·ç¾îÁø´Ù. ù¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼ ÇÁ·ÎÆ®·Òºó Ȱ¼ºÁ¦¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ ÇÁ·ÎÆ®·Òºó Ȱ¼ºÁ¦¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ Ç÷¾×¼Ó¿¡ ÀÖ´Â ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. |
||
| ¿µ¹® | fasting blood sugar | ÇÑ±Û | °øº¹Ç÷´ç, ºó¼ÓÇ÷´ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×¼Ó¿¡ Æ÷ÇԵǾî ÀÖ´Â Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dLÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀÏ Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â âÀÚ°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ ÀÖ¾î¼ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë, ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇÏ°Ô °ü°èÇÑ´Ù. ƯÈ÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù. |
||
| ¿µ¹® | white blood cell(WBC), leukocyte | ÇÑ±Û | ¹éÇ÷±¸ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, ȤÀº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀÎ Çö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | whole blood | ÇÑ±Û | ÀüÇ÷, ¿ÂÇ÷¾× |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÇ ¸ðµç ¼ººÐÀÌ Çϳªµµ Á¦°ÅµÇÁö ¾ÊÀº ¿ÂÀüÇÑ Ç÷¾×. ÀüÇ÷Àº ¾ö°ÝÇÑ ¹«±ÕÁ¶°ÇÇÏ¿¡¼, ¼±º°ÇÑ °øÇ÷ÀڷκÎÅÍ Ã¤ÃëÇÑ °ÍÀ̸ç, ±¸¿¬»ê ÀÌ¿ÂÀ̳ª ÇìÆÄ¸° °°Àº Ç×ÀÀ°øÁ¦·Î ÀÀ°í¸¦ ¹æÁöÇÏ¿© Ç÷¾×º¸Ãæ ¸ñÀûÀ¸·Î »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | blood collection | ÇÑ±Û | äÇ÷ |
|---|---|---|---|
| ¼³¸í | 1. ¸ð¼¼°üÇ÷ : Ç÷±¸¼ö-Ç÷¼ÒÆÇ¼ö °è»ê, Ç÷»ö¼Ò·®, Ç÷±¸¿ëÀûÃøÁ¤, µµ¸»Ç¥º»Á¦ÀÛ µîÀ» ÇÒ¶§ »ç¿ëµÈ´Ù. ±ÓºÒ ¶Ç´Â ¼Õ°¡¶ô³¡¹Ù´Ú¸éÀ» ÃæºÐÈ÷ ¸¶ÂûÇÑ ´ÙÀ½, ¾ËÄڿ÷Π¼Òµ¶-°ÇÁ¶½ÃÄѼ, ÀÛÀº Ä® ¶Ç´Â Á¾µÎħ ȤÀº 1mmÀÇ ÁÖ»çħÀ¸·Î 2~3mmÀÇ ±íÀ̱îÁö Â´Ù. ¸ÇóÀ½ Çǹæ¿ïÀº ´Û¾Æ³½ ÈÄ ´ÙÀ½ Ç͹æ¿ïÀ» °Ë»ç¿¡ ÀÌ¿ëÇÑ´Ù. 2. Á¤¸ÆÇ÷ : ´ë·®ÀÇ Ç÷¾×À» ¿äÇÏ´Â °æ¿ì¿¡ »ç¿ëÇÑ´Ù. º¸Åë (ÆÈ²ÞÄ¡Á¤ÁßÇǺÎ)ÁÖÁ¤ÁßÇÇÁ¤¸ÆÀ» Â¸ç, ¿µÀ¯¾ÆÀÇ °æ¿ì¿¡´Â ¿Ü°æÁ¤¸ÆÀ» ¼±ÅÃÇϱ⵵ ÇÑ´Ù. ÁöÇ÷¿ë °í¹«ÁÙ·Î »ó´ÜÀ» ÃÖÀúÇ÷¾Ð¿¡ »ó´çÇÏ´Â Á¤µµ·Î ¹°í, ÁÖ¸ÔÀ» ²À Áã°Ô ÇÏ¿© Á¤¸ÆÀ» ³ëÃâ½ÃŲ ÈÄ ¸ê±Õ°ÇÁ¶ÁÖ»ç±â¸¦ Ç÷°ü³»¿¡ »ðÀÔÇÑ´Ù. °ð ¹Ù·Î °í¹«ÁÙ°ú ÁÖ¸ÔÀ» Ç®°í äÇ÷À» ÇÑ ´ÙÀ½ Ç÷¾×À» ½ÃÇè°ü¿¡ ³Ö´Â´Ù. 2ºÐÀÌ»óÀÇ Á¤¸Æ ¿ïÇ÷Àº Ç÷¾×¼º»ó¿¡ º¯È¸¦ °¡Á®¿Â´Ù. 2. µ¿¸ÆÇ÷ : À§ÆÈµ¿¸Æ ¶Ç´Â ³Ò´Ù¸® µ¿¸ÆÀ» »ç¿ëÇÏ¿© õÀںθ¦ ¼Òµ¶ÇÑ ´ÙÀ½, ÇÁ·ÎÄ«ÀÎ ±¹¼Ò¸¶Ã븦 ÇÑ´Ù. äÇ÷ÀÚ ¿Þ¼ÕÀÇ °¡¿îµ¥¼Õ°¡¶ô°ú µÑ°¼Õ°¡¶ôÀ¸·Î µ¿¸ÆÀ» °íÁ¤Çϰí, ÁÖ»çħÀ» µ¿¸Æ¿¡ 45~65¡ÉÀÇ °¢µµ·Î Âñ·¯ ³Ö¾î äÇ÷ ÈÄ ¸öÂʵ¿¸ÆÀ» ¾öÁö¼Õ°¡¶ôÀ¸·Î ¾Ð¹ÚÇÏ¸é¼ ÁÖ»çħÀ» »©°í, ±× µÚ 5ºÐ°£Âë Â ºÎÀ§¸¦ ¾Ð¹ÚÇÑ´Ù. |
||
| CBV | capillary blood cell velocity; catheter balloon valvuloplasty; central blood volume; cerebral blood ... |
|---|---|
| CBF | capillary blood flow; cerebral blood flow; ciliary beat frequency; coronary blood flow; cortical blo... |
| HBF | hand blood flow; hemispheric blood flow; hemoglobinuric bilious fever; hepatic blood flow; hypothala... |
| ICA | 1) Islet Cell Antibody 2) Internal Carotid Artery |
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
| IBF | islet blood flow |
|---|---|
| IAPP | Islet amyloid polypeptide |
| ICA | Islet Cell-Cytoplasmic Antibodies |
| IAP | Islet activating protein |
| ICA | Islet cell |
| blood islet | An aggregation of splanchnic mesodermal cells on the embryonic yolk sac, with the potentiality of forming vascular endothelium and primitive blood cells. Synonym: blood islet. (05 Mar 2000) |
|---|
| adenoma, islet cell | A benign tumour of the islets of langerhans that may occur anywhere throughout the pancreas. Such tumours may result in hyperinsulinism or zollinger-ellison syndrome. (12 Dec 1998) |
|---|---|
| carcinoma, islet cell | A carcinoma of the islets of langerhans. (12 Dec 1998) |
| pancreatic isleT-cell tumours | <radiology> Insulinoma (beta-cell), usually solitary, 85% benign, gastrinoma, small, slow-growing, multiple, 60% malignant, Zollinger-Ellison syndrome: mult. Intractable ulcers, VIPoma, vasoactive intestinal peptide (VIP), WDHA syndrome: watery diarrhoea, hypokalaemia, achlorhydria, Verner-Morrison syndrome, glucagonoma, hyperglycaemia, migratory necrolytic erythema APUDomas, associated with MEN-1 (12 Dec 1998) |
| islet | A small island. (05 Mar 2000) |
| islet amyloid peptide | <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide. (15 Oct 1997) |
| islet cell | <pathology> Cells of the Islets of Langerhans within the pancreas. See: A cells, B-cells, D cells. (18 Nov 1997) |
| islet cell adenoma | <tumour> A benign neoplasm of the pancreas composed of tissue similar in structure to that of the islets of Langerhans; it may contain functioning beta cells, and may cause hypoglycaemia. See: insulinoma. Synonym: nesidioblastoma. (05 Mar 2000) |
| islet cell antibodies | In first-degree relatives of probands with insulin-dependent diabetes mellitus the presence of high titre ICA of the IgG cytoplasmic variety (IgG -ICA) and ICA of the complement-fixing subgroup (CF-ICA) confer a relative risk of 75 for development of insulin-dependent diabetes mellitus. The presence of ICA combined with a decrease in the first-phase of insulin secretion ( less than 25 micro U/mL) is predictive with a 95% likelihood of the development of insulin-dependent diabetes mellitus within 12 months. Reproducible results among laboratories are possible with careful attention to selection of the human pancreas as substrate as well as to the use of dilutions to generate standard curves and to the conversion of results to units. The prozone phenomena described elsewhere are not common in our experience. Fifty percent of relatives with a single positive ICA test will develop insulin-dependent diabetes mellitus within 10 years, and 60-80% of relatives with both ICA and insulin autoantibodies (IAA) will develop insulin-dependent diabetes mellitus within 10 years. The predictive value for health of negative results for ICA and IAA is almost 99%. Strong, persistently positive ICA (i.e., 40 JDF U or greater), especially if accompanied by markedly decreased insulin secretion, are the best predictors of subsequent development of insulin-dependent diabetes mellitus. The 64 kD beta-cell autoantigen long thought to be an important target for ICA is not yet available from expression cloning despite efforts by several groups.13 ICA positivity correlates with rapid loss of C-peptide secretory capacity in newly diagnosed ICA-positive insulin-dependent diabetes mellitus. The predictive values of ICA for development of insulin-dependent diabetes mellitus within 10 years in first-degree relatives of patients with insulin-dependent diabetes mellitus increase from 40% at low levels of ICA to 100% at high levels, whereas the sensitivity is 88% at low levels and 31% at high levels. In general, the risk of insulin-dependent diabetes mellitus in relatives of probands increases with titre of ICA, is greater in multiplex families, and is increased in those less than 10 years of age with positive ICA. Although the prevalence of ICA in Japanese with autoimmune thyroid disease resembles that in Caucasians, the incidence of insulin-dependent diabetes mellitus in the Japanese population is only 1/30 - 1/50 that in Caucasians. Prediabetics positive for ICA and IAA have increased suppressor-inducer (CD45R) and decreased helper-inducer (CDw29) peripheral blood lymphocytes. In two randomised, prospective, placebo-controlled studies of recent-onset insulin-dependent diabetes mellitus, cyclosporine immunosuppression increased the rate of non-insulin-requiring remissions as well as beta-cell function during drug treatment. Although 12 months of cyclosporine therapy decreases titres of ICA and insulin antibodies (IA) and increases glucagon-stimulated levels of serum C-peptide, the determination of ICA and IA and HLA-DR type are of no predictive value in selecting recent- onset insulin-dependent diabetes mellitus. Patients for cyclosporine immunointervention. Genetic control of autoimmunity in insulin-dependent diabetes mellitus is reviewed. EIA for autoantibodies to a 64 kD islet-cell protein is promising for prediction of insulin-dependent diabetes mellitus, but sensitivity and specificity are still suboptimal. See also: insulin antibodies. (05 Mar 2000) |
| islet cell antigen-related protein-tyrosine phosphatase | <enzyme> Receptor-like autoantigen found in insulin-dependent diabetes; genbank l76258 Registry number: EC 3.1.3.- Synonym: iar ptp (26 Jun 1999) |
| islet-cell-stimulating antibodies | <immunology> Autoantibodies to a putative beta-cell receptor; stimulate the release of insulin both in rodents and man; may be analogous to the thyroid stimulating antibodies that cause grave's hyperthyroidism Synonym: icsta (05 Dec 1998) |
| islet neogenesis-associated protein | <chemical> Constituent of ilotropin; stimulates proliferation of pancreatic ductal cells in vitro; from hamsters and humans; amino acid sequence given in first source Synonym: ingap protein, ingap gene product (05 Dec 1998) |
| islet tissue | <anatomy> Groups of cells found within the pancreas: A cells and B-cells secrete insulin and glucagon. See: D cells. (18 Nov 1997) |
| ABO blood group | <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells. According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom. Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood. Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors. And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction. (04 Jul 1999) |
| Almen's test for blood | Glacial acetic acid, gum guaiac solution, and hydrogen peroxide are added to an aqueous suspension of the suspected stain; if occult blood or blood pigment is present, a blue colour develops. Synonym: guaiac test, Schonbein's test, van Deen's test. (05 Mar 2000) |
| arterial blood | Blood that is oxygenated in the lungs, found in the left chambers of the heart and in the arteries, and relatively bright red. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|